GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery

The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition

(2012) K Siddiquee et al.   BRITISH JOURNAL OF PHARMACOLOGY

Apo-Ghrelin Receptor Forms Heteromers with DRD2 in Hypothalamic Neurons and Is Essential for Anorexigenic Effects of DRD2 Agonism

(2012) Andras Kern et al.   NEURON

Biased signalling and allosteric machines: new vistas and challenges for drug discovery

(2011) Terry P Kenakin   BRITISH JOURNAL OF PHARMACOLOGY

Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely

(2011) Xiao Sun et al.   HYPERTENSION RESEARCH

Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production

(2011) Khandaker Siddiquee et al.   JOURNAL OF HYPERTENSION

Dimers and beyond: The functional puzzles of class C GPCRs

(2011) Julie Kniazeff et al.   PHARMACOLOGY & THERAPEUTICS

Molecular organization and dynamics of the melatonin MT1 receptor/RGS20/Gi protein complex reveal asymmetry of receptor dimers for RGS and Gi coupling

(2010) Pascal Maurice et al.   EMBO JOURNAL

Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes

(2010) N. J. Smith et al.   PHARMACOLOGICAL REVIEWS

Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation

(2009) Yang Han et al.   Nature Chemical Biology